Simpson Thacher represented the underwriters, led by BofA Securities, HSBC and Mizuho Securities, in the U.S. registered public offering by AstraZeneca PLC of $3 billion of senior notes with maturities ranging between five and thirty years. The offering closed on August 6, 2020, with the net proceeds being used for general corporate purposes, which may include the refinancing of existing indebtedness.
AstraZeneca is a global, science-led, patient-focused pharmaceutical business that focuses on the discovery, development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca’s ordinary shares are admitted to trading on the London Stock Exchange and its American Depositary Shares are listed on the New York Stock Exchange, both under the symbol “AZN.”
The Simpson Thacher team included Mark Brod, Srishti Gupta and Alexander Leicht (Capital Markets); Jonathan Cantor (Tax); Vanessa Burrows (Healthcare Regulatory); Jennie Getsin (FINRA and Blue Sky); and Alysha Sekhon (IP).